Ocrevus® (ocrelizumab) Ocrevus Zunovo™ (ocrelizumab and hyaluronidase-ocsq)

Ocrevus and Ocrevus Zunovo are covered only for the FDA‑approved adult indications—relapsing forms of MS (including clinically isolated syndrome, relapsing‑remitting, and active secondary progressive) and primary progressive MS—and uses in patients <18 or non‑FDA indications are not covered. Coverage requires age ≥18, prescription by or consultation with a neurologist/MS specialist, 12‑month initial and renewal authorizations with dosing per the prescribing information, and for reauthorization after ≥12 months documentation of objective clinical benefit or stabilization/improvement (e.g., MRI, EDSS, NEDA‑3/4, relapse reduction, functional tests or symptom improvement).

"Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults"

Sign up to see full coverage criteria, indications, and limitations.